MSF Field Research > 1 Published Research and Commentary > Health Politics > A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

Please use this identifier to cite or link to this item: http://hdl.handle.net/10144/220355
    Del.icio.us     LinkedIn     Citeulike     Connotea     Facebook     Stumble it!


Download this article:
View/Open File Description Size Format
Thumbnail
View/Open
111012_A win-win-solution-A-critical-analysis-of-tiered-pricing-to-improve-access-to-medicines-in-developing-countries_Globalization-and-Health-7-39.pdfMain article962KbAdobe PDF

Title: A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries
Authors: Moon, Suerie
Jambert, Elodie
Childs, Michelle
von Schoen-Angerer, Tido
Affiliation: Harvard Kennedy School and School of Public Health, Boston, USA; Médecins Sans Frontières, Campaign for Access to Essential Medicines, Geneva, Switzerland
Citation: Globalization and Health 2011; 7:39
Publisher: BioMed Central
Journal: Globalization and Health
Issue Date: 12-Oct-2011
URI: http://hdl.handle.net/10144/220355
DOI: 10.1186/1744-8603-7-39
PubMed ID: 21992405
Additional Links: http://www.globalizationandhealth.com/content/7/1/39
Abstract: Background: Tiered pricing - the concept of selling drugs and vaccines in developing countries at prices systematically lower than in industrialized countries - has received widespread support from industry, policymakers, civil society, and academics as a way to improve access to medicines for the poor. We carried out case studies based on a review of international drug price developments for antiretrovirals, artemisinin combination therapies, drug-resistant tuberculosis medicines, liposomal amphotericin B (for visceral leishmaniasis), and pneumococcal vaccines. Discussion: We found several critical shortcomings to tiered pricing: it is inferior to competition for achieving the lowest sustainable prices; it often involves arbitrary divisions between markets and/or countries, which can lead to very high prices for middle-income markets; and it leaves a disproportionate amount of decision-making power in the hands of sellers vis-à-vis consumers. In many developing countries, resources are often stretched so tight that affordability can only be approached by selling medicines at or near the cost of production. Policies that “de-link” the financing of R&D from the price of medicines merit further attention, since they can reward innovation while exploiting robust competition in production to generate the lowest sustainable prices. However, in special cases - such as when market volumes are very small or multi-source production capacity is lacking - tiered pricing may offer the only practical option to meet short-term needs for access to a product. In such cases, steps should be taken to ensure affordability and availability in the longer-term. Summary: To ensure access to medicines for populations in need, alternate strategies should be explored that harness the power of competition, avoid arbitrary market segmentation, and/or recognize government responsibilities. Competition should generally be the default option for achieving affordability, as it has proven superior to tiered pricing for reliably achieving the lowest sustainable prices.
Type: Article
Language: en
MeSH: Developing Countries
Health Policy
ISSN: 1744-8603
Rights: Archived with thanks to Globalization and Health's Open Access policy
Appears in topics: Health Politics

Related articles on PubMed
bullet
bullet
bullet
bullet
bullet
See all 115 articles

All Items in MSF are protected by copyright, with all rights reserved, unless otherwise indicated.

 

OR Logo Powered by Open Repository | Cookies

My MSF

MSF logo MSF Field Research

Apr 20, 2014